Andi George is a senior reviewer for the Office of Biotechnology Products (OBP) in the Center for Drug Evaluation and Research (CDER) at FDA. She serves as a member of the ICH Q12 working group in OBP and participated in the Established Conditions Pilot Program in 2019. Before joining FDA, Dr. George studied mammary stem cell biology as a post-doctoral fellow at the National Institutes of Health (NIH). Dr. George received her Ph.D. in Microbiology and Immunology from New York Medical College in Valhalla, NY. |